Jinyao Biotechnology (Tianjin) Co., Ltd. (Jinyao Biotechnology) is a wholly-owned subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd. (“Tianjin Pharma”). Tianjin Pharma is a large-scale pharmaceutical enterprise group with a relatively complete chain of pharmaceutical industry in China, integrating scientific research, production, and commercial sales, and has been selected as one of the Top 100 Pharmaceutical Industries in China for many years. Tianjin Pharma has rich product resources, with more than 1,000 product approvals covering a wide range of traditional Chinese medicines, chemical medicines, and medical devices.

Jinyao Biotechnology, the bio-innovative drug R&D platform of Tianjin Pharma, was incorporated in Hedong District, Tianjin on October 15, 2020, with a registered capital of RMB 500 million. Jinyao Biotechnology has more than 40 employees, with 80% of the employees with master’s degree or above. It has been recognized as a national-level sci-tech small and medium-sized enterprise, an eyas program enterprise in Tianjin and an innovative small and medium-sized enterprise in Tianjin.

Jinyao Biotechnology, with the cutting-edge development direction of bio-innovative drugs, has laid out its business in autoimmune, respiratory, inflammation, ophthalmology and other fields. By taking the “independent development + external introduction” as the main business development mode, it has deeply explored and selected high-quality projects of bio-innovative drugs with a globalized vision; it also has actively constructed and perfected the system of introducing, evaluating, and transforming bio-innovative drugs with the help of experts’ resources. The MAH + CXO) + VC mode is employed to accelerate the transformation and incubation process of bio-innovative drugs. In terms of independent development, Jinyao Biotechnology carries out research with focus on small-molecule chemical drugs and in parallel with new molecular structural entities and innovative complex preparation technologies. In corporation with Nankai University, it has established an AI-based new drug screening and design platform, a pharmacological evaluation platform for asthma, rheumatoid arthritis, psoriasis, atopic dermatitis, and acute kidney injury, and a platform for analyzing innovative drugs. In terms of business cooperation and introduction, Jinyao Biotechnology attaches importance to the projects that have the possibility of being listed within five years and are expected to become the top three in China. It has established cooperative relationships with many domestic and foreign databases, famous investment institutions, biotech companies, and scientific research institutions to look for cooperation opportunities.